ELLIPTIC LABORATORIES ASA (ELABS.OL) Fundamental Analysis & Valuation

OSL:ELABS • NO0010722283

Current stock price

2.945 NOK
+0.17 (+6.32%)
Last:

This ELABS.OL fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

0

1. ELABS.OL Profitability Analysis

1.1 Basic Checks

  • In the past year ELABS has reported negative net income.
  • In the past year ELABS had a positive cash flow from operations.
  • In the past 5 years ELABS reported 4 times negative net income.
  • ELABS had negative operating cash flow in 4 of the past 5 years.
ELABS.OL Yearly Net Income VS EBIT VS OCF VS FCFELABS.OL Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -50M -100M

1.2 Ratios

  • ELABS has a worse Return On Assets (-50.31%) than 90.27% of its industry peers.
  • With a Return On Equity value of -58.76%, ELABS is not doing good in the industry: 84.96% of the companies in the same industry are doing better.
Industry RankSector Rank
ROA -50.31%
ROE -58.76%
ROIC N/A
ROA(3y)-23.6%
ROA(5y)-16.65%
ROE(3y)-27.51%
ROE(5y)-19.19%
ROIC(3y)N/A
ROIC(5y)N/A
ELABS.OL Yearly ROA, ROE, ROICELABS.OL Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -20 -40 -60

1.3 Margins

  • The Profit Margin and Operating Margin and Gross Margin are not available for ELABS so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ELABS.OL Yearly Profit, Operating, Gross MarginsELABS.OL Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -100 -200 -300 -400

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

5

2. ELABS.OL Health Analysis

2.1 Basic Checks

  • ELABS does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • ELABS has about the same amout of shares outstanding than it did 1 year ago.
  • ELABS has more shares outstanding than it did 5 years ago.
  • ELABS has a worse debt/assets ratio than last year.
ELABS.OL Yearly Shares OutstandingELABS.OL Yearly Shares OutstandingYearly Shares Outstanding 2017 2018 2019 2020 2021 2022 2023 2024 2025 20M 40M 60M 80M 100M
ELABS.OL Yearly Total Debt VS Total AssetsELABS.OL Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2017 2018 2019 2020 2021 2022 2023 2024 2025 100M 200M 300M

2.2 Solvency

  • ELABS has a Debt/Equity ratio of 0.04. This is a healthy value indicating a solid balance between debt and equity.
  • The Debt to Equity ratio of ELABS (0.04) is better than 81.42% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.04
Debt/FCF N/A
Altman-Z N/A
ROIC/WACCN/A
WACC8.75%
ELABS.OL Yearly LT Debt VS Equity VS FCFELABS.OL Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 100M 200M 300M

2.3 Liquidity

  • ELABS has a Current Ratio of 5.61. This indicates that ELABS is financially healthy and has no problem in meeting its short term obligations.
  • ELABS's Current ratio of 5.61 is amongst the best of the industry. ELABS outperforms 90.27% of its industry peers.
  • A Quick Ratio of 5.61 indicates that ELABS has no problem at all paying its short term obligations.
  • ELABS has a better Quick ratio (5.61) than 90.27% of its industry peers.
Industry RankSector Rank
Current Ratio 5.61
Quick Ratio 5.61
ELABS.OL Yearly Current Assets VS Current LiabilitesELABS.OL Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2017 2018 2019 2020 2021 2022 2023 2024 2025 50M 100M 150M 200M 250M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

6

3. ELABS.OL Growth Analysis

3.1 Past

  • The earnings per share for ELABS have decreased strongly by -1437.50% in the last year.
  • The Revenue has been growing slightly by 2.69% in the past year.
  • ELABS shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 27.37% yearly.
EPS 1Y (TTM)-1437.5%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-1000%
Revenue 1Y (TTM)2.69%
Revenue growth 3Y24.85%
Revenue growth 5Y27.37%
Sales Q2Q%-12.39%

3.2 Future

  • ELABS is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 68.73% yearly.
  • ELABS is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 25.74% yearly.
EPS Next Y146.21%
EPS Next 2Y68.73%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year37.18%
Revenue Next 2Y38.44%
Revenue Next 3YN/A
Revenue Next 5Y25.74%

3.3 Evolution

  • When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is stable.
ELABS.OL Yearly Revenue VS EstimatesELABS.OL Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2029 2030 2031 2032 2033 200M 400M 600M
ELABS.OL Yearly EPS VS EstimatesELABS.OL Yearly EPS VS EstimatesYearly EPS VS Estimates 2022 2023 2024 2025 2026 2027 0 0.5 -0.5 -1

More info and screens

Find the best growth stocksShow best growing peers

5

4. ELABS.OL Valuation Analysis

4.1 Price/Earnings Ratio

  • ELABS reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • The Price/Forward Earnings ratio is 5.96, which indicates a rather cheap valuation of ELABS.
  • Based on the Price/Forward Earnings ratio, ELABS is valued cheaper than 96.46% of the companies in the same industry.
  • ELABS is valuated cheaply when we compare the Price/Forward Earnings ratio to 22.84, which is the current average of the S&P500 Index.
Industry RankSector Rank
PE N/A
Fwd PE 5.96
ELABS.OL Price Earnings VS Forward Price EarningsELABS.OL Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30

4.2 Price Multiples

  • Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of ELABS is on the same level as its industry peers.
Industry RankSector Rank
P/FCF N/A
EV/EBITDA 23.67
ELABS.OL Per share dataELABS.OL EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5 1 -1 1.5

4.3 Compensation for Growth

  • The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
  • ELABS's earnings are expected to grow with 68.73% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y68.73%
EPS Next 3YN/A

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. ELABS.OL Dividend Analysis

5.1 Amount

  • No dividends for ELABS!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

ELABS.OL Fundamentals: All Metrics, Ratios and Statistics

ELLIPTIC LABORATORIES ASA

OSL:ELABS (4/1/2026, 7:00:00 PM)

2.945

+0.17 (+6.32%)

Chartmill FA Rating
GICS IndustryGroupSoftware & Services
GICS IndustrySoftware
Earnings (Last)02-26
Earnings (Next)N/A
Inst Owners34.57%
Inst Owner ChangeN/A
Ins Owners8.59%
Ins Owner ChangeN/A
Market Cap371.98M
Revenue(TTM)135.47M
Net Income(TTM)-111.52M
Analysts84.44
Price Target19.38 (558.06%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-335.44%
Min EPS beat(2)-585.44%
Max EPS beat(2)-85.44%
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-33.5%
Min Revenue beat(2)-33.83%
Max Revenue beat(2)-33.17%
Revenue beat(4)0
Avg Revenue beat(4)-30.74%
Min Revenue beat(4)-45.84%
Max Revenue beat(4)-10.11%
Revenue beat(8)1
Avg Revenue beat(8)-18.51%
Revenue beat(12)2
Avg Revenue beat(12)-25.07%
Revenue beat(16)3
Avg Revenue beat(16)-19.78%
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 5.96
P/S 2.75
P/FCF N/A
P/OCF 62.06
P/B 1.96
P/tB 3.14
EV/EBITDA 23.67
EPS(TTM)-1.07
EYN/A
EPS(NY)0.49
Fwd EY16.79%
FCF(TTM)-0.18
FCFYN/A
OCF(TTM)0.05
OCFY1.61%
SpS1.07
BVpS1.5
TBVpS0.94
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -50.31%
ROE -58.76%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-23.6%
ROA(5y)-16.65%
ROE(3y)-27.51%
ROE(5y)-19.19%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0.61
Health
Industry RankSector Rank
Debt/Equity 0.04
Debt/FCF N/A
Debt/EBITDA 0.57
Cap/Depr 114.84%
Cap/Sales 21.47%
Interest Coverage N/A
Cash Conversion 41.48%
Profit Quality N/A
Current Ratio 5.61
Quick Ratio 5.61
Altman-Z N/A
F-Score3
WACC8.75%
ROIC/WACCN/A
Cap/Depr(3y)137.42%
Cap/Depr(5y)166.05%
Cap/Sales(3y)29.77%
Cap/Sales(5y)33.28%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-1437.5%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-1000%
EPS Next Y146.21%
EPS Next 2Y68.73%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)2.69%
Revenue growth 3Y24.85%
Revenue growth 5Y27.37%
Sales Q2Q%-12.39%
Revenue Next Year37.18%
Revenue Next 2Y38.44%
Revenue Next 3YN/A
Revenue Next 5Y25.74%
EBIT growth 1Y-289.39%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year394.12%
EBIT Next 3YN/A
EBIT Next 5Y76.86%
FCF growth 1Y43.83%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y156.51%
OCF growth 3YN/A
OCF growth 5YN/A

ELLIPTIC LABORATORIES ASA / ELABS.OL Fundamental Analysis FAQ

Can you provide the ChartMill fundamental rating for ELLIPTIC LABORATORIES ASA?

ChartMill assigns a fundamental rating of 3 / 10 to ELABS.OL.


Can you provide the valuation status for ELLIPTIC LABORATORIES ASA?

ChartMill assigns a valuation rating of 5 / 10 to ELLIPTIC LABORATORIES ASA (ELABS.OL). This can be considered as Fairly Valued.


How profitable is ELLIPTIC LABORATORIES ASA (ELABS.OL) stock?

ELLIPTIC LABORATORIES ASA (ELABS.OL) has a profitability rating of 0 / 10.


How financially healthy is ELLIPTIC LABORATORIES ASA?

The financial health rating of ELLIPTIC LABORATORIES ASA (ELABS.OL) is 5 / 10.